US EditionProspective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors
- Belay Diagnostics has partnered with GenomOncology to enhance cancer care through their Summit and Vantage tests, which provide liquid biopsy capabilities for CNS tumor detection.
- The collaboration aims to streamline the testing workflow for CNS tumors using the GO Pathology Workbench, which will process DNA samples more efficiently.
- Dr. Honey Reddi of Belay Diagnostics stated that their CSF liquid biopsy assay offers an innovative alternative to existing diagnostic methods for CNS cancer detection.
- A webinar hosted by Dr. Reddi on April 9 will educate on using the GO Pathology Workbench for diagnosing CNS tumors.
23 Articles
23 Articles
Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors
Molecular data integration plays a central role in central nervous system (CNS) tumor diagnostics but currently used assays pose limitations due to technical complexity, equipment and reagent costs, as well as lengthy turnaround times. We previously reported the development of Rapid-CNS2, an adaptive-sampling-based nanopore sequencing workflow. Here we comprehensively validated and further developed Rapid-CNS2 for intraoperative use. It now offe…
hartfordcitynewstimes.com
Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection
CLEVELAND, March 25, 2025 /PRNewswire/ -- Belay Diagnostics announces its partnership with GenomOncology (GO), a precision medicine software company that provides data-driven tools and resources to improve cancer care. To streamline the tertiary analysis of their Summit™ test, as well…
Coverage Details
Bias Distribution
- 70% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
